{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:01:07Z","timestamp":1782698467229,"version":"3.54.5"},"reference-count":131,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.3892\/mmr.2017.7487","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T09:45:29Z","timestamp":1505295929000},"page":"6443-6458","source":"Crossref","is-referenced-by-count":15,"title":["Targeting strategies of adenovirus-mediated gene therapy and virotherapy for prostate cancer"],"prefix":"10.3892","volume":"16","author":[{"given":"Zhonglin","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidi","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangzhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,9,13]]},"reference":[{"key":"key20180108004109_b1-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0734-9750(02)00030-7","article-title":"Production of adenovirus vector for gene therapy","volume":"20","author":"Nadeau","year":"2003","journal-title":"Biotechnol Adv"},{"key":"key20180108004109_b2-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3181\/00379727-84-20714","article-title":"Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture","volume":"84","author":"Rowe","journal-title":"Proc Soc Exp Biol Med"},{"key":"key20180108004109_b3-mmr-16-05-6443","first-page":"616","article-title":"Development of adenovirus vectors for the expression of heterologous genes","volume":"6","author":"Berkner","year":"1988","journal-title":"Biotechniques"},{"key":"key20180108004109_b4-mmr-16-05-6443","first-page":"39","article-title":"Expression of heterologous sequences in adenoviral vectors","volume":"158","author":"Berkner","year":"1992","journal-title":"Curr Top Microbiol Immunol"},{"key":"key20180108004109_b5-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1073\/pnas.91.13.6196","article-title":"Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver","volume":"91","author":"Engelhardt","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108004109_b6-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"8459","DOI":"10.1128\/JVI.70.12.8459-8467.1996","article-title":"Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence","volume":"70","author":"Hehir","year":"1996","journal-title":"J Virol"},{"key":"key20180108004109_b7-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1128\/JVI.71.4.3293-3298.1997","article-title":"A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging","volume":"71","author":"Parks","year":"1997","journal-title":"J Virol"},{"key":"key20180108004109_b8-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/sj.gt.3301668","article-title":"Replication and packaging of helper-dependent adenoviral vectors","volume":"9","author":"Sato","year":"2002","journal-title":"Gene Ther"},{"key":"key20180108004109_b9-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/hum.1996.7.3-301","article-title":"Safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of nonhuman primates","volume":"7","author":"Wilmott","year":"1996","journal-title":"Hum Gene Ther"},{"key":"key20180108004109_b10-mmr-16-05-6443","first-page":"3","article-title":"Adenovirus-mediated cancer gene therapy and virotherapy (Review)","volume":"25","author":"Fukazawa","year":"2010","journal-title":"Int J Mol Med"},{"key":"key20180108004109_b11-mmr-16-05-6443","first-page":"1161","article-title":"Adenoviral gene therapy for cancer: From vectors to targeted and replication competent agents (Review)","volume":"21","author":"Bauerschmitz","year":"2002","journal-title":"Int J Oncol"},{"key":"key20180108004109_b12-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/156800907780618301","article-title":"Conditionally replicating adenoviruses for cancer treatment","volume":"7","author":"Jounaidi","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"key20180108004109_b13-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/gt.2008.40","article-title":"Taming the Trojan horse: Optimizing dynamic carrier cell\/oncolytic virus systems for cancer biotherapy","volume":"15","author":"Power","year":"2008","journal-title":"Gene Ther"},{"key":"key20180108004109_b14-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.4161\/cbt.29842","article-title":"Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells","volume":"15","author":"Wei","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"key20180108004109_b15-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1016\/j.biomaterials.2014.03.060","article-title":"Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression","volume":"35","author":"Lee","year":"2014","journal-title":"Biomaterials"},{"key":"key20180108004109_b16-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy","volume":"6","author":"Heise","year":"2000","journal-title":"Nat Med"},{"key":"key20180108004109_b17-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial","volume":"360","author":"Andriole","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180108004109_b18-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1442-2042.2000.00221.x","article-title":"Diagnostic value of prostate-specific antigen-related parameters in discriminating prostate cancer","volume":"7","author":"Matsuyama","year":"2000","journal-title":"Int J Urol"},{"key":"key20180108004109_b19-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000474493","article-title":"Free\/total prostate-specific antigen ratio-hope and controversies","volume":"31","author":"Ravery","year":"1997","journal-title":"Eur Urol"},{"key":"key20180108004109_b20-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180108004109_b21-mmr-16-05-6443","first-page":"184","article-title":"The new human tissue kallikrein gene family: Structure, function, and association to disease","volume":"22","author":"Yousef","year":"2001","journal-title":"Endocr Rev"},{"key":"key20180108004109_b22-mmr-16-05-6443","first-page":"5453","article-title":"CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity","volume":"61","author":"Chen","year":"2001","journal-title":"Cancer Res"},{"key":"key20180108004109_b23-mmr-16-05-6443","first-page":"2559","article-title":"Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells","volume":"57","author":"Rodriguez","year":"1997","journal-title":"Cancer Res"},{"key":"key20180108004109_b24-mmr-16-05-6443","first-page":"7464","article-title":"A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"DeWeese","year":"2001","journal-title":"Cancer Res"},{"key":"key20180108004109_b25-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3892\/or.2015.4454","article-title":"Selective and augmented \u03b2-glucuronidase expression combined with DOX-GA3 application elicits the potent suppression of prostate cancer","volume":"35","author":"Wang","year":"2016","journal-title":"Oncol Rep"},{"key":"key20180108004109_b26-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0006-291X(82)91725-9","article-title":"Isolation and characterization of androgen-dependent non-histone chromosomal protein from dorsolateral prostate of rats","volume":"109","author":"Matuo","year":"1982","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180108004109_b27-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.1073\/pnas.86.20.7843","article-title":"Regulation of a bifunctional mRNA results in synthesis of secreted and nuclear probasin","volume":"86","author":"Spence","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108004109_b28-mmr-16-05-6443","first-page":"230","article-title":"The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice","volume":"8","author":"Greenberg","year":"1994","journal-title":"Mol Endocrinol"},{"key":"key20180108004109_b29-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/gt.2010.63","article-title":"A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer","volume":"17","author":"Trujillo","year":"2010","journal-title":"Gene Ther"},{"key":"key20180108004109_b30-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/jnci\/93.17.1314","article-title":"Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells","volume":"93","author":"Andriani","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"key20180108004109_b31-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00259-013-2374-2","article-title":"PSMA as a target for radiolabelled small molecules","volume":"40","author":"Eder","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"key20180108004109_b32-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s001200050041","article-title":"Significance of prostate-specific membrane antigen (PSMA). A neurocarboxypeptidase and membrane folate hydrolase","volume":"35","author":"Heston","year":"1996","journal-title":"Urologe A"},{"key":"key20180108004109_b33-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/pros.21241","article-title":"High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer","volume":"71","author":"Minner","year":"2011","journal-title":"Prostate"},{"key":"key20180108004109_b34-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1006\/geno.1995.0019","article-title":"Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11","volume":"30","author":"Rinker-Schaeffer","year":"1995","journal-title":"Genomics"},{"key":"key20180108004109_b35-mmr-16-05-6443","first-page":"6357","article-title":"Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer","volume":"9","author":"Ross","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key20180108004109_b36-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","article-title":"Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases","volume":"52","author":"Sweat","year":"1998","journal-title":"Urology"},{"key":"key20180108004109_b37-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/pros.22627","article-title":"Prostate specific membrane antigen (PSMA): A novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells","volume":"73","author":"Zhang","year":"2013","journal-title":"Prostate"},{"key":"key20180108004109_b38-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4103\/1008-682X.122354","article-title":"Radioiodine therapy for castration-resistant prostate cancer following prostate-specific membrane antigen promoter-mediated transfer of the human sodium iodide symporter","volume":"16","author":"Gao","year":"2014","journal-title":"Asian J Androl"},{"key":"key20180108004109_b39-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2164\/jandrol.107.002519","article-title":"Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer\/promoter","volume":"28","author":"Zeng","year":"2007","journal-title":"J Androl"},{"key":"key20180108004109_b40-mmr-16-05-6443","first-page":"5975","article-title":"DD3: A new prostate-specific gene, highly overexpressed in prostate cancer","volume":"59","author":"Bussemakers","year":"1999","journal-title":"Cancer Res"},{"key":"key20180108004109_b41-mmr-16-05-6443","first-page":"2695","article-title":"DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors","volume":"62","author":"de Kok","year":"2002","journal-title":"Cancer Res"},{"key":"key20180108004109_b42-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0302-2838(03)00201-X","article-title":"DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer","volume":"44","author":"Hessels","year":"2003","journal-title":"Eur Urol"},{"key":"key20180108004109_b43-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/ijc.25069","article-title":"Targeting Gene-ViroTherapy for prostate cancer by DD3-driven oncolytic virus-harboring interleukin-24 gene","volume":"127","author":"Fan","year":"2010","journal-title":"Int J Cancer"},{"key":"key20180108004109_b44-mmr-16-05-6443","first-page":"679","article-title":"Construction of an oncolytic adenovirus expressing small hairpin RNA and targeting the SATB1 gene","volume":"16","author":"Mao","year":"2010","journal-title":"Zhonghua Nan Ke Xue"},{"key":"key20180108004109_b45-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1126\/science.279.5349.349","article-title":"Extension of life-span by introduction of telomerase into normal human cells","volume":"279","author":"Bodnar","year":"1998","journal-title":"Science"},{"key":"key20180108004109_b46-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/hmg\/8.1.137","article-title":"The human telomerase catalytic subunit hTERT: Organization of the gene and characterization of the promoter","volume":"8","author":"Cong","year":"1999","journal-title":"Hum Mol Genet"},{"key":"key20180108004109_b47-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.gt.3301619","article-title":"hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity","volume":"9","author":"Gu","year":"2002","journal-title":"Gene Ther"},{"key":"key20180108004109_b48-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/(SICI)1097-0215(19990315)80:6<804::AID-IJC2>3.0.CO;2-B","article-title":"Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors","volume":"80","author":"Kyo","year":"1999","journal-title":"Int J Cancer"},{"key":"key20180108004109_b49-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<330::AID-CNCR22>3.0.CO;2-W","article-title":"Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia","volume":"78","author":"Bostwick","year":"1996","journal-title":"Cancer"},{"key":"key20180108004109_b50-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/cncr.10988","article-title":"Telomerase reverse transcriptase subunit immunoreactivity: A marker for high-grade prostate carcinoma","volume":"95","author":"Iczkowski","year":"2002","journal-title":"Cancer"},{"key":"key20180108004109_b51-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/(SICI)1096-9896(199910)189:2<213::AID-PATH417>3.0.CO;2-A","article-title":"Expression of the RNA component of human telomerase (hTR) in prostate cancer, prostatic intraepithelial neoplasia, and normal prostate tissue","volume":"189","author":"Paradis","year":"1999","journal-title":"J Pathol"},{"key":"key20180108004109_b52-mmr-16-05-6443","first-page":"619","article-title":"Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium","volume":"58","author":"Zhang","year":"1998","journal-title":"Cancer Res"},{"key":"key20180108004109_b53-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3892\/or.2013.2738","article-title":"Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines","volume":"30","author":"Sato","year":"2013","journal-title":"Oncol Rep"},{"key":"key20180108004109_b54-mmr-16-05-6443","first-page":"333","article-title":"Oncolytic adenovirus-induced autophagy: Tumor-suppressive effect and molecular basis","volume":"67","author":"Tazawa","year":"2013","journal-title":"Acta Med Okayama"},{"key":"key20180108004109_b55-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1158\/1078-0432.CCR-13-0742","article-title":"A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells in S\/G2\/M phases","volume":"19","author":"Yano","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20180108004109_b56-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/jor.23073","article-title":"Eradication of osteosarcoma by fluorescence-guided surgery with tumor labeling by a killer-reporter adenovirus","volume":"34","author":"Yano","year":"2016","journal-title":"J Orthop Res"},{"key":"key20180108004109_b57-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"e0148760","DOI":"10.1371\/journal.pone.0148760","article-title":"Improved resection and outcome of colon-cancer liver metastasis with fluorescence-guided surgery using in situ GFP labeling with a telomerase-dependent adenovirus in an orthotopic mouse model","volume":"11","author":"Yano","year":"2016","journal-title":"PLoS One"},{"key":"key20180108004109_b58-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"75635","DOI":"10.18632\/oncotarget.12314","article-title":"Fluorescence-guided surgery of a highly-metastatic variant of human triple-negative breast cancer targeted with a cancer-specific GFP adenovirus prevents recurrence","volume":"7","author":"Yano","year":"2016","journal-title":"Oncotarget"},{"key":"key20180108004109_b59-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/cgt.2008.3","article-title":"Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model","volume":"15","author":"Huang","year":"2008","journal-title":"Cancer Gene Ther"},{"key":"key20180108004109_b60-mmr-16-05-6443","first-page":"1252","article-title":"The animal research of recombinant adenovirus controlled by human telomerase reverse transcriptase promoter in the treatment of human prostate cancer","volume":"44","author":"Zhang","year":"2006","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"key20180108004109_b61-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nm.2269","article-title":"Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression","volume":"17","author":"Bhang","year":"2011","journal-title":"Nat Med"},{"key":"key20180108004109_b62-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/mt.2009.252","article-title":"Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach","volume":"18","author":"Greco","year":"2010","journal-title":"Mol Ther"},{"key":"key20180108004109_b63-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"14034","DOI":"10.1073\/pnas.0506837102","article-title":"Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice","volume":"102","author":"Sarkar","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108004109_b64-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1073\/pnas.0409141102","article-title":"Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter","volume":"102","author":"Su","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108004109_b65-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"9125","DOI":"10.1073\/pnas.94.17.9125","article-title":"Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene","volume":"94","author":"Su","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108004109_b66-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1158\/0008-5472.CAN-07-0195","article-title":"Eradication of therapy-resistant human prostate tumors using a cancer terminator virus","volume":"67","author":"Sarkar","year":"2007","journal-title":"Cancer Res"},{"key":"key20180108004109_b67-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"12723","DOI":"10.1016\/S0021-9258(17)44236-0","article-title":"Matrix sialoprotein of developing bone","volume":"258","author":"Fisher","year":"1983","journal-title":"J Biol Chem"},{"key":"key20180108004109_b68-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"7949","DOI":"10.1074\/jbc.M211915200","article-title":"Delineation of the hydroxyapatite-nucleating domains of bone sialoprotein","volume":"278","author":"Tye","year":"2003","journal-title":"J Biol Chem"},{"key":"key20180108004109_b69-mmr-16-05-6443","first-page":"4060","article-title":"Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer","volume":"7","author":"Fedarko","year":"2001","journal-title":"Clin Cancer Res"},{"key":"key20180108004109_b70-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jcp.21576","article-title":"Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells","volume":"218","author":"Tu","year":"2009","journal-title":"J Cell Physiol"},{"key":"key20180108004109_b71-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/jnci\/90.13.1000","article-title":"Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer","volume":"90","author":"Waltregny","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"key20180108004109_b72-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.urolonc.2005.11.003","article-title":"Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model","volume":"24","author":"Canales","year":"2006","journal-title":"Urol Oncol"},{"key":"key20180108004109_b73-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.urolonc.2009.08.012","article-title":"Conditionally replicating adenovirus therapy utilizing bone sialoprotein promoter (Ad-BSP-E1a) in an in vivo study of treating androgen-independent intraosseous prostate cancer","volume":"29","author":"Li","year":"2011","journal-title":"Urol Oncol"},{"key":"key20180108004109_b74-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.3109\/0284186X.2010.542174","article-title":"Tumor markers in prostate cancer I: Blood-based markers","volume":"50","author":"Shariat","year":"2011","journal-title":"Acta Oncol"},{"key":"key20180108004109_b75-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1158\/1078-0432.CCR-10-0122","article-title":"A four-kallikrein panel predicts prostate cancer in men with recent screening: Data from the European randomized study of screening for prostate cancer, rotterdam","volume":"16","author":"Vickers","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20180108004109_b76-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.eururo.2008.11.040","article-title":"Screening for prostate cancer in 2008 II: The importance of molecular subforms of prostate-specific antigen and tissue kallikreins","volume":"55","author":"Jansen","year":"2009","journal-title":"Eur Urol"},{"key":"key20180108004109_b77-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/ijc.21474","article-title":"Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum","volume":"118","author":"Steuber","year":"2006","journal-title":"Int J Cancer"},{"key":"key20180108004109_b78-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"e107819","DOI":"10.1371\/journal.pone.0107819","article-title":"Proteolytic activity of prostate-specific antigen (PSA) towards protein substrates and effect of peptides stimulating PSA activity","volume":"9","author":"Mattsson","year":"2014","journal-title":"PLoS One"},{"key":"key20180108004109_b79-mmr-16-05-6443","first-page":"1498","article-title":"Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy","volume":"59","author":"Yu","year":"1999","journal-title":"Cancer Res"},{"key":"key20180108004109_b80-mmr-16-05-6443","first-page":"903","article-title":"Differential expression of osteocalcin during the metastatic progression of prostate cancer","volume":"21","author":"Gardner","year":"2009","journal-title":"Oncol Rep"},{"key":"key20180108004109_b81-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10585-013-9626-1","article-title":"Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies","volume":"31","author":"Thulin","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"key20180108004109_b82-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/S0022-5347(05)65250-0","article-title":"Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer","volume":"167","author":"Koizumi","year":"2002","journal-title":"J Urol"},{"key":"key20180108004109_b83-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/1055-9965.EPI-08-0554","article-title":"Serum undercarboxylated osteocalcin as biomarker of vitamin K intake and risk of prostate cancer: A nested case-control study in the Heidelberg cohort of the European prospective investigation into cancer and nutrition","volume":"18","author":"Nimptsch","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20180108004109_b84-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/pros.21442","article-title":"GPRC6A regulates prostate cancer progression","volume":"72","author":"Pi","year":"2012","journal-title":"Prostate"},{"key":"key20180108004109_b85-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s003450050181","article-title":"Osteocalcin-directed gene therapy for prostate-cancer bone metastasis","volume":"18","author":"Koeneman","year":"2000","journal-title":"World J Urol"},{"key":"key20180108004109_b86-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/10430340360535788","article-title":"Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer","volume":"14","author":"Kubo","year":"2003","journal-title":"Hum Gene Ther"},{"key":"key20180108004109_b87-mmr-16-05-6443","first-page":"6012","article-title":"A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis","volume":"61","author":"Matsubara","year":"2001","journal-title":"Cancer Res"},{"key":"key20180108004109_b88-mmr-16-05-6443","first-page":"3084","article-title":"A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors","volume":"62","author":"Hsieh","year":"2002","journal-title":"Cancer Res"},{"key":"key20180108004109_b89-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1038\/onc.2010.194","article-title":"Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1","volume":"29","author":"Dash","year":"2010","journal-title":"Oncogene"},{"key":"key20180108004109_b90-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1038\/onc.2011.496","article-title":"Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61","volume":"31","author":"Harris","year":"2012","journal-title":"Oncogene"},{"key":"key20180108004109_b91-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/jcb.22075","article-title":"Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status","volume":"106","author":"Lv","year":"2009","journal-title":"J Cell Biochem"},{"key":"key20180108004109_b92-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"10712","DOI":"10.18632\/oncotarget.3544","article-title":"Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic","volume":"6","author":"Sarkar","year":"2015","journal-title":"Oncotarget"},{"key":"key20180108004109_b93-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1006\/mthe.2002.0682","article-title":"Novel prostate-specific promoter derived from PSA and PSMA enhancers","volume":"6","author":"Lee","year":"2002","journal-title":"Mol Ther"},{"key":"key20180108004109_b94-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1089\/hum.2011.021","article-title":"In vitro primary cell culture as a physiologically relevant method for preclinical testing of human oncolytic adenovirus","volume":"23","author":"Adamson","year":"2012","journal-title":"Hum Gene Ther"},{"key":"key20180108004109_b95-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.cgt.7700881","article-title":"An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer","volume":"13","author":"Cheng","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"key20180108004109_b96-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.cgt.7701117","article-title":"Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I\/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region","volume":"15","author":"Danielsson","year":"2008","journal-title":"Cancer Gene Ther"},{"key":"key20180108004109_b97-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.cgt.7701007","article-title":"Two-step amplification of the human PPT sequence provides specific gene expression in an immunocompetent murine prostate cancer model","volume":"14","author":"Dzojic","year":"2007","journal-title":"Cancer Gene Ther"},{"key":"key20180108004109_b98-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ymthe.2004.05.022","article-title":"A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer","volume":"10","author":"Cheng","year":"2004","journal-title":"Mol Ther"},{"key":"key20180108004109_b99-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/pros.20560","article-title":"A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors","volume":"67","author":"Kraaij","year":"2007","journal-title":"Prostate"},{"key":"key20180108004109_b100-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3109\/09553000903419338","article-title":"Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer","volume":"86","author":"Liu","year":"2010","journal-title":"Int J Radiat Biol"},{"key":"key20180108004109_b101-mmr-16-05-6443","first-page":"120","article-title":"A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency","volume":"7","author":"Suzuki","year":"2001","journal-title":"Clin Cancer Res"},{"key":"key20180108004109_b102-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/labinvest.2012.179","article-title":"Expression of osteoprotegerin from a replicating adenovirus inhibits the progression of prostate cancer bone metastases in a murine model","volume":"93","author":"Cody","year":"2013","journal-title":"Lab Invest"},{"key":"key20180108004109_b103-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/hum.2013.229","article-title":"ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models","volume":"25","author":"Dong","year":"2014","journal-title":"Hum Gene Ther"},{"key":"key20180108004109_b104-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/hum.2011.016","article-title":"A transductionally retargeted adenoviral vector for virotherapy of Her2\/neu-expressing prostate cancer","volume":"23","author":"Magnusson","year":"2012","journal-title":"Hum Gene Ther"},{"key":"key20180108004109_b105-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"e0147173","DOI":"10.1371\/journal.pone.0147173","article-title":"Arg-Gly-Asp (RGD)-modified E1A\/E1B double mutant adenovirus enhances antitumor activity in prostate cancer cells in vitro and in mice","volume":"11","author":"Shen","year":"2016","journal-title":"PLoS One"},{"key":"key20180108004109_b106-mmr-16-05-6443","first-page":"34","article-title":"Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5\/3-CTV)","volume":"229","author":"Azab","year":"2014","journal-title":"J Cell Physiol"},{"key":"key20180108004109_b107-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/cgt.2013.4","article-title":"Effect of increased viral replication and infectivity enhancement on radioiodide uptake and oncolytic activity of adenovirus vectors expressing the sodium iodide symporter","volume":"20","author":"Oneal","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"key20180108004109_b108-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.1158\/1078-0432.CCR-08-2571","article-title":"Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter","volume":"15","author":"Hakkarainen","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180108004109_b109-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-06-0403","article-title":"Treatment of prostate cancer with Ad5\/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo","volume":"6","author":"Rajecki","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"key20180108004109_b110-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/mt.2014.80","article-title":"Ad5\/48 hexon oncolytic virus expressing sTGF\u03b2RIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases","volume":"22","author":"Xu","year":"2014","journal-title":"Mol Ther"},{"key":"key20180108004109_b111-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2147\/OTT.S51749","article-title":"Development of an immunotherapeutic adenovirus targeting hormone-independent prostate cancer","volume":"6","author":"Kim","year":"2013","journal-title":"Onco Targets Ther"},{"key":"key20180108004109_b112-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.canlet.2015.12.018","article-title":"Ad5\/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA\/PSMA transcription regulatory elements","volume":"372","author":"Hwang","year":"2016","journal-title":"Cancer Lett"},{"key":"key20180108004109_b113-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nm0697-639","article-title":"ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents","volume":"3","author":"Heise","year":"1997","journal-title":"Nat Med"},{"key":"key20180108004109_b114-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1007\/s13277-015-3658-x","article-title":"Oncolytic virus carrying shRNA targeting SATB1 inhibits prostate cancer growth and metastasis","volume":"36","author":"Mao","year":"2015","journal-title":"Tumour Biol"},{"key":"key20180108004109_b115-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"e35153","DOI":"10.1371\/journal.pone.0035153","article-title":"Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene","volume":"7","author":"Ding","year":"2012","journal-title":"PLoS One"},{"key":"key20180108004109_b116-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1089\/hum.2010.019","article-title":"Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts","volume":"21","author":"Radhakrishnan","year":"2010","journal-title":"Hum Gene Ther"},{"key":"key20180108004109_b117-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1078-0432.CCR-09-1960","article-title":"Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers","volume":"16","author":"Oberg","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20180108004109_b118-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.urology.2007.09.031","article-title":"Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus","volume":"70","author":"Satoh","year":"2007","journal-title":"Urology"},{"key":"key20180108004109_b119-mmr-16-05-6443","first-page":"7464","article-title":"A phase I trial of CV706, a replication-competent, PAS selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"DeWeese","year":"2001","journal-title":"Cancer Res"},{"key":"key20180108004109_b120-mmr-16-05-6443","first-page":"4968","article-title":"Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer","volume":"62","author":"Freytag","year":"2002","journal-title":"Cancer Res"},{"key":"key20180108004109_b121-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/sj.mt.6300068","article-title":"Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer","volume":"15","author":"Freytag","year":"2007","journal-title":"Mol Ther"},{"key":"key20180108004109_b122-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymthe.2006.02.011","article-title":"A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer","volume":"14","author":"Small","year":"2006","journal-title":"Mol Ther"},{"key":"key20180108004109_b123-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20180108004109_b124-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Breitbach","year":"2011","journal-title":"Nature"},{"key":"key20180108004109_b125-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1586\/14737140.2015.1115725","article-title":"Clinical development of talimogene laherparepvec (T-VEC): A modified herpes simplex virus type-1-derived oncolytic immunotherapy","volume":"15","author":"Harrington","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20180108004109_b126-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"624632","DOI":"10.1155\/2013\/624632","article-title":"Comparison of prostate-specific promoters and the use of PSP-driven virotherapy for prostate cancer","volume":"2013","author":"Lu","year":"2013","journal-title":"Biomed Res Int"},{"key":"key20180108004109_b127-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.cgt.7700451","article-title":"Transcription-targeted gene therapy for androgen-independent prostate cancer","volume":"9","author":"Martiniello-Wilks","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"key20180108004109_b128-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.3892\/ijo.2013.1783","article-title":"Potent growth-inhibitory effect of a dual cancer-specific oncolytic adenovirus expressing apoptin on prostate carcinoma","volume":"42","author":"Zhang","year":"2013","journal-title":"Int J Oncol"},{"key":"key20180108004109_b129-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/104303401300042483","article-title":"Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter","volume":"12","author":"Xie","year":"2001","journal-title":"Hum Gene Ther"},{"key":"key20180108004109_b130-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/0008-5472.CAN-04-3666","article-title":"Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer","volume":"65","author":"Li","year":"2005","journal-title":"Cancer Res"},{"key":"key20180108004109_b131-mmr-16-05-6443","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/cgt.2009.62","article-title":"Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL","volume":"17","author":"Jimenez","year":"2010","journal-title":"Cancer Gene Ther"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T19:54:49Z","timestamp":1659470089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mmr.2017.7487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":131,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,9,13]]},"published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.3892\/mmr.2017.7487"],"URL":"https:\/\/doi.org\/10.3892\/mmr.2017.7487","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}